REG - Abingdon Health PLC - Director Share Transfer to Trust

Abingdon HealthAnnouncement

01/03/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230301:nRSA3985Ra&default-theme=true

RNS Number : 3985R  Abingdon Health PLC  01 March 2023

Abingdon Health plc

("Abingdon Health" or "the Company")

 

Director Share Transfer to Trust

 

York, U.K. 1 March 2023: Abingdon Health plc (AIM: ABDX), a leading
international lateral flow contract development and manufacturing organisation
(CDMO), announces that it received notification on 28 February 2023 that Dr
Chris Hand, Non-executive Chairman, transferred 3,000,000 ordinary shares of
0.025 pence each in the Company ("Ordinary Shares") from his personal account
into The CW Hand 2023 Settlement, a discretionary trust in which Dr Hand is a
trustee. Dr Hand retains an additional 10,027,667 Ordinary Shares outside of
the trust.

 

Dr Hand has advised the Company that he has no intention of selling Ordinary
Shares, either from those held inside the trust or those held outside of the
trust.

 

Following this transaction the percentage of Ordinary Shares that Dr Hand
retains outside of the trust combined with those for which he is a trustee
remains at 10.7 per cent.

 

Further details are set out in the PDMR form below, made in accordance with
the Market Abuse Regulation (EU) No. 596/2014 which is part of UK law by
virtue of the European Union (Withdrawal) Act 2018.

 

Enquiries

 

 Abingdon Health plc                                              www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Yates, Chief Executive Officer                             Via Walbrook PR
 Melanie Ross, Chief Financial Officer
 Chris Hand, Non-Executive Chairman

 Singer Capital Markets (Sole Broker and Nominated Adviser)       Tel: +44 (0)20 7496 3000
 Peter Steel, Alex Bond (Corporate Finance)
 Tom Salvesen (Corporate Broking)

 Walbrook PR Limited              Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                  (mailto:abingdon@walbrookpr.com)
 Paul McManus / Phillip Marriage  Mob: +44 (0)7980 541 893 / +44 (0)7867 984 082

 Alice Woodings                   +44 (0)7407 804 654

 

About Abingdon Health plc

 

Abingdon Health is a leading lateral flow contract development and
manufacturing organisation ("CDMO") offering its services to an international
customer base across industry sectors that include clinical, animal health,
plant health, and environmental testing. Abingdon Health has the internal
capabilities to take projects from initial concept through to routine and
large-scale manufacturing; from "idea to commercial success."

 

The Company's CDMO division offers product development, regulatory support,
technology transfer and manufacturing services for customers looking to
develop new assays or transfer existing laboratory-based assays to a lateral
flow format. Abingdon Health aims to support the increase in need for rapid
results across many industries and locations and produces lateral flow tests
in areas such as infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access to results
allows for rapid decision making, targeted intervention and can support better
outcomes.

 

Abingdon Health's Abingdon Simply Test range of self-tests is an ecommerce
platform that offers a range of self-tests to empowers consumers to manage
their own health and wellbeing. The Abingdon Simply Test
(http://www.abingdonsimplytest.com) ecommerce site offers consumers a range of
information to support them in making informed decisions on the tests
available. In addition, the site provides Abingdon's contract services
customers with a potential route to market for self-tests. The Abingdon Simply
Test range is also sold through international distributors and through other
channels in the UK and Ireland such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

 

For more information visit: www.abingdonhealth.com
(http://www.abingdonhealth.com/)

 

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         Dr Chris Hand

 2    Reason for the notification

 a)   Position/status                                              Non-executive Chairman

 b)   Initial notification /Amendment                              Initial Notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Abingdon Health plc

 b)   LEI                                                          213800XFI4WV3FBILO20

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 0.025 pence each

      Identification code                                          GB00BLF79J41

 b)   Nature of the transaction                                    Transfer of 3,000,000 Ordinary Shares to The CW Hand 2023 Settlement Trust

 c)   Price(s) and volume(s)                                                        Price            Volume

                                                                                    N/A              3,000,000
 d)   Aggregated information                                                        n/a single transaction

 e)   Date of the transaction                                      28 February 2023

 f)   Place of the transaction                                     Off market

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUWABRORUUUAR